GlassScriptPhysician profile
Deborah Cohan
NPI 1982832671
$8,725.10
in general payments reported to CMS, 2019-2025
28 companies · $919 in 2025
The $919 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,587 · 2022: $3,135 · 2023: $1,374 · 2024: $709 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,947 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,946.87 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,874.94 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,849.71 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,768.69 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $797.12 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $348.34 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $192.56 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $178.89 | 2021-2022 | |
| Amgen INC. | $168.47 | 2021-2025 | Tezspire |
| Pfizer INC. | $165.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.46 | 2021-2023 | Cuvitru |
| Leo Pharma INC. | $145.75 | 2022-2023 | Adbry |
| Grifols USA, LLC | $127.47 | 2021-2023 | Xembify |
| Genentech USA, INC. | $125.57 | 2021-2022 | |
| Csl Behring | $103.23 | 2021-2023 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.00 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $87.50 | 2023-2024 | Ryaltris |
| Pharming Healthcare, INC. | $84.28 | 2021-2022 | |
| Covis Pharma Gmbh | $81.42 | 2021 | |
| Kaleo, INC. | $80.49 | 2021-2023 | Auvi-Q |
| Optinose US, INC. | $77.78 | 2021-2022 | |
| Horizon Therapeutics Plc | $61.85 | 2021-2023 | Actimmune |
| Phadia US INC. | $27.80 | 2023 | Immunocap |
| Abbvie INC. | $27.15 | 2023 | |
| Invivyd INC | $26.64 | 2025 | Pemgarda |
| Biohaven Pharmaceutical Holding Company LTD. | $20.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.62 | 2023 | Trulance, Xifaxan |
| Lucid Diagnostics INC. | $17.11 | 2023 | |
| Incyte Corporation | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Cohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.